AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16059696 — intervention group
Group type: EXPERIMENTAL
Intervention: PFN
Number of subjects: 120
Study 15341662 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocus sativus (saffron) 30 mg/day (TDS)
Number of subjects: 30
Study 15341662 — intervention group
Group type: COMPARATOR
Intervention: Imipramine 100 mg/day (TDS)
Number of subjects: 30
Study 10733632 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath-PUVA
Number of subjects: 34
Study 10733632 — intervention group
Group type: COMPARATOR
Intervention: Oral-PUVA
Number of subjects: 34
Study 9368235 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium levels in blood serum, red blood cells, and hair
Number of subjects: 116
Study 9368235 — intervention group
Group type: COMPARATOR
Intervention: Magnesium levels
Number of subjects: 116
Study 7716695 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 1
Study 7716695 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 1
Study 7716695 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride
Number of subjects: 1
Study 7716695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 3885668 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic catheter drainage
Number of subjects: 92
Study 3885668 — intervention group
Group type: COMPARATOR
Intervention: Transurethral catheter drainage
Number of subjects: 92
Study 3282814 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitive PEEP (determined by blood gas criteria)
Number of subjects: 118
Study 3282814 — intervention group
Group type: COMPARATOR
Intervention: Supportive PEEP (the minimal PEEP required to maintain PaO2 above 60 mm Hg on 0.5 inspired O2 fraction)
Number of subjects: 118
Study 31028212 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month exercise intervention
Number of subjects: 444
Study 28687347 — intervention group
Group type: EXPERIMENTAL
Intervention: TT-173 (2mg over surgical surfaces)
Number of subjects: 189
Study 28687347 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline (control)
Number of subjects: 189
Study 25260393 — intervention group
Group type: EXPERIMENTAL
Intervention: Fu Zheng decoction combined with antibiotics
Number of subjects: 0
Study 25260393 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic only treatment
Number of subjects: 0
Study 25260393 — intervention group
Group type: EXPERIMENTAL
Intervention: Fu Zheng decoction
Number of subjects: 0
Study 24097199 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted sun protection intervention (DVD and booklets)
Number of subjects: 340
Study 21783050 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime Time intervention plus usual clinic services
Number of subjects: 253
Study 21783050 — intervention group
Group type: COMPARATOR
Intervention: Usual clinic services (Control)
Number of subjects: 253
Study 19360898 — intervention group
Group type: EXPERIMENTAL
Intervention: LY450139 (gamma-secretase inhibitor) 100mg
Number of subjects: 15
Study 19360898 — intervention group
Group type: EXPERIMENTAL
Intervention: LY450139 (gamma-secretase inhibitor) 140mg
Number of subjects: 15
Study 19360898 — intervention group
Group type: EXPERIMENTAL
Intervention: LY450139 (gamma-secretase inhibitor) 280mg
Number of subjects: 15
Study 19360898 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 15
Study 16490836 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestrictive visiting policy (UVP)
Number of subjects: 226
Study 16490836 — intervention group
Group type: COMPARATOR
Intervention: Restrictive visiting policy (RVP)
Number of subjects: 226
Study 14758296 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical twitch-obtaining intramuscular stimulation (ETOIMS)
Number of subjects: 12
Study 14758296 — intervention group
Group type: COMPARATOR
Intervention: Muscle stimulation
Number of subjects: 12
Study 14758296 — intervention group
Group type: COMPARATOR
Intervention: Skin stimulation
Number of subjects: 12
Study 11527248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (20 mg/2 mL, or 1 ampoule; Fujisawa, Osaka, Japan) four times daily for 1 week
Number of subjects: 16
Study 11527248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mL of saline) four times daily for 1 week
Number of subjects: 16
Study 9068775 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 700
Study 9068775 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 700
Study 8420685 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 300 mg/m2 plus Cyclophosphamide 600 mg/m2
Number of subjects: 342
Study 8420685 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 plus Cyclophosphamide 600 mg/m2
Number of subjects: 342
Study 3755285 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy
Number of subjects: 184
Study 3755285 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-field radiotherapy
Number of subjects: 184
Study 3755285 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP plus involved-field radiotherapy
Number of subjects: 184
Study 3755285 — intervention group
Group type: COMPARATOR
Intervention: Involved-field radiotherapy and extended-field radiotherapy
Number of subjects: 184
Study 29136387 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 299
Study 29136387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 26718415 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation (0.06 g ∙ kg(‐1) ∙ meal(‐1))
Number of subjects: 19
Study 26718415 — intervention group
Group type: COMPARATOR
Intervention: Alanine control
Number of subjects: 19
Study 26718415 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation
Number of subjects: 19
Study 24027014 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based educational program on colorectal cancer screening plus a reminder call
Number of subjects: 360
Study 24027014 — intervention group
Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 360
Study 23404115 — intervention group
Group type: EXPERIMENTAL
Intervention: RBX 32 mg/d
Number of subjects: 1028
Study 23404115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1028
Study 20828422 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-cooperative path control mode with individually adjusted support
Number of subjects: 11
Study 20828422 — intervention group
Group type: COMPARATOR
Intervention: Non-cooperative position control mode
Number of subjects: 11
Study 20828422 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant impedance control mode
Number of subjects: 11
Study 18243612 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous extract of Astragali Radix (ARE) 0.3g/kg body weight
Number of subjects: 12
Study 18243612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18243612 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous extract of Astragali Radix (ARE)
Number of subjects: 12
Study 15728889 — intervention group
Group type: EXPERIMENTAL
Intervention: Tefibazumab 2 mg/kg
Number of subjects: 19
Study 15728889 — intervention group
Group type: EXPERIMENTAL
Intervention: Tefibazumab 5 mg/kg
Number of subjects: 19
Study 15728889 — intervention group
Group type: EXPERIMENTAL
Intervention: Tefibazumab 10 mg/kg
Number of subjects: 19
Study 15728889 — intervention group
Group type: EXPERIMENTAL
Intervention: Tefibazumab 20 mg/kg
Number of subjects: 19
Study 12853233 — intervention group
Group type: EXPERIMENTAL
Intervention: Arotinolol 10 mg per day
Number of subjects: 175
Study 12853233 — intervention group
Group type: EXPERIMENTAL
Intervention: Arotinolol 20 mg per day
Number of subjects: 175
Study 12853233 — intervention group
Group type: EXPERIMENTAL
Intervention: Arotinolol 30 mg per day
Number of subjects: 175
Study 12853233 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 mg per day
Number of subjects: 175
Study 12853233 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg per day
Number of subjects: 175
Study 12853233 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 160 mg per day
Number of subjects: 175
Study 10491227 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 1,25(OH)2D3 (1.5 microg/m2 BSA)
Number of subjects: 10
Study 10491227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 1,25(OH)2D3 (1.5 microg/m2 BSA)
Number of subjects: 10
Study 10491227 — intervention group
Group type: COMPARATOR
Intervention: Sr absorption without 1,25(OH)2D3 (test A)
Number of subjects: 10
Study 10491227 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of Sr and oral 1,25(OH)2D3 (test B)
Number of subjects: 10
Study 10491227 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of Sr and iv 1,25(OH)2D3 (test C)
Number of subjects: 10
Study 8699600 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral thyroarytenoid muscle injections of 15 units of botulinum toxin
Number of subjects: 50
Study 8699600 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral thyroarytenoid muscle injections of 2.5 units of botulinum toxin on each side
Number of subjects: 50
Study 8699600 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 normal subjects)
Number of subjects: 50
Study 1664833 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral temafloxacin 600 mg twice daily (n = 49)
Number of subjects: 100
Study 1664833 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefotaxime 2 g thrice daily (n = 51)
Number of subjects: 100
Study 7039882 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment (intense immunosuppression followed by long-term maintenance on azathioprine)
Number of subjects: 20
Study 7039882 — intervention group
Group type: COMPARATOR
Intervention: Cells taken from patients before treatment
Number of subjects: 20
Study 7039882 — intervention group
Group type: COMPARATOR
Intervention: Cells from untreated MS patients
Number of subjects: 20
Study 7039882 — intervention group
Group type: COMPARATOR
Intervention: Untreated MS patients
Number of subjects: 20
Study 31693519 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventative multimodal analgesia (PMA) including 1000 mg of acetaminophen, 300-900 mg of gabapentin, and 200-400 mg of celecoxib 1 hour before surgery
Number of subjects: 101
Study 31693519 — intervention group
Group type: COMPARATOR
Intervention: 15 mg of morphine-equivalent dose (MED) preoperatively
Number of subjects: 101
Study 29946148 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin add-on to continuous subcutaneous insulin infusion (Met + CSII)
Number of subjects: 188
Study 29946148 — intervention group
Group type: COMPARATOR
Intervention: Control group (CSII only)
Number of subjects: 188
Study 26787402 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple intake (increase of 53 g/d)
Number of subjects: 1456
Study 26787402 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple intake of 5-100 g/d
Number of subjects: 1456
Study 26787402 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple intake of >100 g/d (an apple a day)
Number of subjects: 1456
Study 26787402 — intervention group
Group type: COMPARATOR
Intervention: Apple intake <5 g/d (control group)
Number of subjects: 1456
Study 26787402 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher apple intake
Number of subjects: 1456
Study 26787402 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total fruit and banana intakes
Number of subjects: 1456
Study 24610902 — intervention group
Group type: COMPARATOR
Intervention: Conservative management without intervention and antithrombotic therapy (control group).
Number of subjects: 113
Study 22583697 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg + metformin
Number of subjects: 288
Study 22583697 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg + metformin
Number of subjects: 288
Study 22583697 — intervention group
Group type: COMPARATOR
Intervention: Placebo + metformin
Number of subjects: 288
Study 22583697 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (12.5 or 25 mg) + metformin
Number of subjects: 288
Study 21280523 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP) of 5 cmH2O
Number of subjects: 61
Study 21280523 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP) of 10 cmH2O
Number of subjects: 61
Study 21280523 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP) of 15 cmH2O
Number of subjects: 61
Study 21280523 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP) of 20 cmH2O
Number of subjects: 61
Study 17270058 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone 8 mg
Number of subjects: 32
Study 17270058 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone 16 mg
Number of subjects: 32
Study 17270058 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone 32 mg
Number of subjects: 32
Study 17270058 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone 64 mg
Number of subjects: 32
Study 17270058 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone (all doses)
Number of subjects: 32
Study 15475600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-lactate infusion (LC) during exercise
Number of subjects: 0
Study 15475600 — intervention group
Group type: COMPARATOR
Intervention: Control (Con) with isotonic, isovolumetric saline infusion during exercise
Number of subjects: 0
Study 12088242 — intervention group
Group type: EXPERIMENTAL
Intervention: Michelson contrast
Number of subjects: 0
Study 9800672 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipelle suction curette
Number of subjects: 79
Study 9800672 — intervention group
Group type: COMPARATOR
Intervention: Vabra aspirating catheter
Number of subjects: 79
Study 8585710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention to instill hope; duration: 4 weeks; specific details on dosage not available.
Number of subjects: 0
Study 8585710 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group; no specific intervention applied.
Number of subjects: 0
Study 2780762 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 vaginal film (850 micrograms)
Number of subjects: 69
Study 2780762 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal film (nonmedicated)
Number of subjects: 69
Study 2780762 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 vaginal film
Number of subjects: 69
Study 2780762 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal film
Number of subjects: 69
Study 4911756 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretylium tosylate
Number of subjects: 101
Study 4911756 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 101
Study 30635222 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal consent process (n=25)
Number of subjects: 50
Study 30635222 — intervention group
Group type: COMPARATOR
Intervention: Standard consent process (n=25)
Number of subjects: 50
Study 27355532 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 447
Study 27355532 — intervention group
Group type: COMPARATOR
Intervention: Control (rabies vaccine)
Number of subjects: 447
Study 25302772 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical prenatal vitamin D intake (334 IU/day)
Number of subjects: 193
Study 25302772 — intervention group
Group type: EXPERIMENTAL
Intervention: Women delivering in summer and fall
Number of subjects: 193
Study 25302772 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-pregnancy plasma 25(OH)D concentration
Number of subjects: 193
Study 25302772 — intervention group
Group type: EXPERIMENTAL
Intervention: Season of birth
Number of subjects: 193
Study 22918824 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA) in post-traumatic osteoarthritis (group PT)
Number of subjects: 43
Study 22918824 — intervention group
Group type: COMPARATOR
Intervention: Matched group with degenerative osteoarthritis (group DO)
Number of subjects: 43
Study 22918824 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty in patients with valgus malalignment > 10° (group PT)
Number of subjects: 43
Study 22918824 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty in patients with degenerative osteoarthritis (group DO)
Number of subjects: 43
Study 20371056 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Partnership Intervention Care (FPIC)
Number of subjects: 56
Study 20371056 — intervention group
Group type: COMPARATOR
Intervention: Conventional Care (CC)
Number of subjects: 56
Study 18534966 — intervention group
Group type: EXPERIMENTAL
Intervention: Low RAS activity
Number of subjects: 18
Study 18534966 — intervention group
Group type: COMPARATOR
Intervention: High RAS activity
Number of subjects: 18
Study 15954973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 4 mg kg(‐1) preoperatively
Number of subjects: 120
Study 15954973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 4 mg kg(‐1) postoperatively
Number of subjects: 120
Study 15954973 — intervention group
Group type: COMPARATOR
Intervention: Normal saline preoperatively and postoperatively (Control group)
Number of subjects: 120
Study 12964500 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day zinc supplementation
Number of subjects: 30
Study 12964500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9781924 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine (80 microg/min)
Number of subjects: 22
Study 9781924 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 22
Study 9781924 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline (NA)
Number of subjects: 22
Study 9781924 — intervention group
Group type: COMPARATOR
Intervention: N(G)-monomethyl-L-arginine (L-NMMA)
Number of subjects: 22
Study 1929105 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily corticosteroid therapy (group A) for an additional year
Number of subjects: 35
Study 1929105 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day corticosteroid therapy (group B) for an additional year
Number of subjects: 35
Study 1929105 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from daily to alternate-day corticosteroid therapy after one year (for group A)
Number of subjects: 35
Study 1929105 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day corticosteroid therapy
Number of subjects: 35
Study 7059094 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion after acid infusion
Number of subjects: 40
Study 7059094 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 40
Study 7059094 — intervention group
Group type: COMPARATOR
Intervention: Placebo-antacid
Number of subjects: 40
Study 7059094 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study 31829510 — intervention group
Group type: EXPERIMENTAL
Intervention: VoluDerm RF technology using the gen100 ultra‐thin electrodes disposable tip
Number of subjects: 12
Study 30682680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate (SVP)
Number of subjects: 118
Study 30682680 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 118
Study 30682680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate (SVP) after crossover from LEV
Number of subjects: 118
Study 30682680 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) after crossover from SVP
Number of subjects: 118
Study 30682680 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall after second AED
Number of subjects: 118
Study 30682680 — intervention group
Group type: COMPARATOR
Intervention: Initial treatment with lorazepam
Number of subjects: 118
Study 27484286 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2963016 insulin glargine (LY IGlar)
Number of subjects: 20
Study 27484286 — intervention group
Group type: COMPARATOR
Intervention: Lantus insulin glargine (IGlar)
Number of subjects: 20
Study 27484286 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LY IGlar and IGlar
Number of subjects: 20
Study 26626539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii training (n = 20)
Number of subjects: 42
Study 26626539 — intervention group
Group type: COMPARATOR
Intervention: Bobath neurodevelopmental treatment (NDT) (n = 22)
Number of subjects: 42
Study 25146692 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG 50 mg q24h for 5 days followed by DTG 50 mg and EFV 600 mg q24h for 14 days
Number of subjects: 30
Study 25146692 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG 50 mg q24h for 5 days followed by TPV/r 500/200 mg q12h for 7 days and then DTG 50 mg q24h and TPV/r 500/200 mg q12h for a further 5 days
Number of subjects: 30
Study 22614936 — intervention group
Group type: COMPARATOR
Intervention: PM (physician management) with weekly buprenorphine dispensing
Number of subjects: 55
Study 22614936 — intervention group
Group type: EXPERIMENTAL
Intervention: PM+DOT/CBT (physician management and directly observed, thrice-weekly buprenorphine with cognitive-behavioral therapy)
Number of subjects: 55
Study 22614936 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT sessions attended
Number of subjects: 55
Study 19066301 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/d for 3 months)
Number of subjects: 33
Study 19066301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 17968836 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral drugs (adamantanes and neuraminidase inhibitors)
Number of subjects: 0
Study 17968836 — intervention group
Group type: COMPARATOR
Intervention: Annual influenza vaccination
Number of subjects: 0
Study 17968836 — intervention group
Group type: COMPARATOR
Intervention: Nonpharmacologic interventions (e.g., handwashing, contact isolation)
Number of subjects: 0
Study 16036028 — intervention group
Group type: EXPERIMENTAL
Intervention: b‐adrenergic receptor antagonists (b‐blockers)
Number of subjects: 0
Study 11575415 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection on median nerve stimulation (group 1)
Number of subjects: 60
Study 11575415 — intervention group
Group type: EXPERIMENTAL
Intervention: Double injection divided between median and radial nerves (group 2)
Number of subjects: 60
Study 9647680 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in Arabic input format
Number of subjects: 1